Swedish Orphan Biovitrum AB (FRA:B6E) Total Liabilities : €3,056 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Total Liabilities?

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Dec. 2024 was €3,056 Mil.

Swedish Orphan Biovitrum AB's quarterly Total Liabilities declined from Jun. 2024 (€3,261.47 Mil) to Sep. 2024 (€3,090.48 Mil) and declined from Sep. 2024 (€3,090.48 Mil) to Dec. 2024 (€3,055.74 Mil).

Swedish Orphan Biovitrum AB's annual Total Liabilities increased from Dec. 2022 (€2,362.37 Mil) to Dec. 2023 (€3,590.19 Mil) but then declined from Dec. 2023 (€3,590.19 Mil) to Dec. 2024 (€3,055.74 Mil).

Swedish Orphan Biovitrum AB Total Liabilities Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Total Liabilities Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2,759.66

2,478.69

2,362.37

3,590.19

3,055.74

Swedish Orphan Biovitrum AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															3,590.19	3,412.32	3,261.47	3,090.48	3,055.74

Swedish Orphan Biovitrum AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Swedish Orphan Biovitrum AB's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1095.403	+	(1101.923	+	858.413
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	3,056

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	6558.855	-	3503.116
	=	3,056

Swedish Orphan Biovitrum AB's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1095.403	+	(1101.923	+	858.413
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	3,056

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	6558.855	-	3503.116
	=	3,056

Swedish Orphan Biovitrum AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (FRA:B6E) » Definitions » Total Liabilities

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines